![]() |
Dr Reddy’s Laboratories: Problems in the Mexico Plant
Introduction
DRL’s Mexican arm, which the company bought from Swiss pharmaceutical major Roche in 2005, produced intermediates and Active Pharmaceutical Ingredients (APIs). After going through the letter twice, Prasad was convinced that he had to take immediate corrective actions (See Exhibit I for a copy of the letter). Though the company had taken some corrective actions following the warning letter and also replied back to the USFDA, it faced this ban. As Prasad looked back at the fond memories following the acquisition in 2005, he wondered what went wrong at the Mexico plant and how could he address them without upsetting the current stakeholders of DRL......
Dri And Its Business Segments- Next Page>>



